# Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis

> **NCT01473797** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 10 (actual)

## Conditions studied

- Langerhans Cell Histiocytosis of Lung

## Interventions

- **DRUG:** Cladribine

## Key facts

- **NCT ID:** NCT01473797
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11
- **Primary completion:** 2018-04
- **Final completion:** 2022-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473797, "Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01473797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*